Medivir - Science working wonders

Improving life for cancer patients

Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.

For those most in need

Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.

Our projects >

Partnering for breadth and depth

Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.

Partnership >

Portfolio highlights

Fostroxacitabine bralpamide (fostrox)

Nucleotide DNA polymerase inhibitor (oral)

More about Fostroxacitabine bralpamide (fostrox)

Birinapant/IGM-9427

SMAC mimetic (intravenous)

More about Birinapant/IGM-9427
View all our current projects

News

2023/06/02

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

Read more
2023/06/01

Medivir to present at the Redeye Growth Day

Read more
2023/05/31

Change in the number of shares and votes in Medivir AB (publ)

Read more
See all

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.

Read more